BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor as its primary technology platform. Biomimetic Therapeutics Inc. has a market cap of $79.8 million; its shares were traded at around $3.3 with and P/S ratio of 46.3.
CEO Samuel Lynch increased his positions in BMTI during the first quarter of 2012. In total, he purchased about $83,000 shares of the company at an average price of $2.40. Additional, the company’s CFO also increased his positions in the company in the first quarter of 2012.
No gurus currently hold any stakes in BMTI.
Since BMTI went public in 2006, the company has consistently negative earnings per share. Revenue per share has seen dramatic decreases, from $0.26 in 2006 to $0.06 in 2011. The company reported a loss in 2011 of $1.19 per share. The company has $61 million in cash and no long-term debt.